title: Relative Timing Between Kappa Opioid Receptor Activation and Cocaine Determines the Impact on Reward and Dopamine Release.
abstract: Negative affective states can increase the rewarding value of drugs of abuse and promote drug taking. Chronic cocaine exposure increases levels of the neuropeptide dynorphin, an endogenous ligand at kappa opioid receptors (KOR) that suppresses dopamine release in the nucleus accumbens (NAc) and elicits negative affective states upon drug withdrawal. However, there is evidence that the effects of KOR activation on affective state are biphasic: immediate aversive effects are followed by delayed increases in reward. The impact of KOR-induced affective states on reward-related effects of cocaine over time is not known. We hypothesize that the initial aversive effects of KOR activation increase, whereas the delayed rewarding effects decrease, the net effects of cocaine on reward and dopamine release. We treated rats with cocaine at various times (15 min to 48 h) after administration of the selective KOR agonist salvinorin A (salvA). Using intracranial self-stimulation and fast scan cyclic voltammetry, we found that cocaine-induced increases in brain stimulation reward and evoked dopamine release in the NAc core were potentiated when cocaine was administered within 1 h of salvA, but attenuated when administered 24 h after salvA. Quantitative real-time PCR was used to show that KOR and prodynorphin mRNA levels were decreased in the NAc, whereas tyrosine hydroxylase and dopamine transporter mRNA levels and tissue dopamine content were increased in the ventral tegmental area 24 h post-salvA. These findings raise the possibility that KOR activation-as occurs upon withdrawal from chronic cocaine-modulates vulnerability to cocaine in a time-dependent manner.
authors.affiliation: Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA, USA.
authors.forename: Elena H
authors.initials: EH
authors.lastname: Chartoff
authors.affiliation: Department of Psychology, University of Illinois at Chicago, Chicago, IL, USA.
authors.forename: Shayla R
authors.initials: SR
authors.lastname: Ebner
authors.affiliation: Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA, USA.
authors.forename: Angela
authors.initials: A
authors.lastname: Sparrow
authors.affiliation: Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA, USA.
authors.forename: David
authors.initials: D
authors.lastname: Potter
authors.affiliation: Graduate Program in Neuroscience, University of Illinois at Chicago, Chicago, IL, USA.
authors.forename: Phillip M
authors.initials: PM
authors.lastname: Baker
authors.affiliation: Department of Psychology, University of Illinois at Chicago, Chicago, IL, USA.
authors.forename: Michael E
authors.initials: ME
authors.lastname: Ragozzino
authors.affiliation: Department of Psychology, University of Illinois at Chicago, Chicago, IL, USA.
authors.forename: Mitchell F
authors.initials: MF
authors.lastname: Roitman
mesh_terms: D000339:Affect / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D003042:Cocaine / Q000008:administration & dosage*; D045785:Diterpenes, Clerodane / Q000008:administration & dosage; D004298:Dopamine / Q000235:genetics / Q000378:metabolism*; D008297:Male; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000378:metabolism / Q000502:physiology*; D012201:Reward; D012653:Self Stimulation / Q000187:drug effects; D013997:Time Factors; D017557:Ventral Tegmental Area / Q000187:drug effects / Q000378:metabolism*
chemical_list: D045785:Diterpenes, Clerodane; D017473:Receptors, Opioid, kappa; D003042:Cocaine; C090499:salvinorin A; D004298:Dopamine